Number of the records: 1  

Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens

  1. 1.
    0450910 - ÚEB 2016 RIV US eng J - Journal Article
    Vymětalová, Ladislava - Kryštof, Vladimír
    Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
    Medicinal Research Reviews. Roč. 35, č. 6 (2015), s. 1156-1174. ISSN 0198-6325. E-ISSN 1098-1128
    R&D Projects: GA MŠMT(CZ) LO1204; GA ČR(CZ) GA15-15264S
    Institutional support: RVO:61389030
    Keywords : cyclin-dependent kinase * inhibitor * cancer
    Subject RIV: FR - Pharmacology ; Medidal Chemistry
    Impact factor: 9.135, year: 2015

    Developments in genetic and genomic technology have produced vast quantities of data that are gradually yielding new insights into fundamental cellular and molecular processes. In particular, they have revealed some differences between normal and transformed cells that could potentially be exploited to develop targeted, personalized cancer therapies with unprecedented efficiencies. This review summarizes recent findings from synthetic lethality (SL) screens against cyclin-dependent kinases (CDKs) that can be targeted with small molecule kinase inhibitors. SL screens can be used to identify cancers sensitive to CDK inhibitors. Several SL partners of specific CDKs have been identified, including MYC, K-Ras, VHL, PI3K, and PARP, all of which are discussed in the review. CDK inhibitors have been in clinical trials for nearly 20 years and it has become clear that effective therapy using these compounds will require careful selection of patients with respect to the specific molecular phenotype of their disease.
    Permanent Link: http://hdl.handle.net/11104/0252096

     
    FileDownloadSizeCommentaryVersionAccess
    2015_Vymetalova_MEDICINAL RESEARCH REVIEWS_1156.pdf6448.6 KBOtheropen-access
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.